 |
|
|
| |
Evaluation of the Health Outcomes for Ledipasvir / Sofosbuvir in Early vs. Delayed Treatment According to the Fibrosis Stage of Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a Decision-Analytic Markov Model....... "initiating earlier LDV/SOF treatment at F0-2 vs F3/4 reduced liver disease progression/sequalae by 66-82% & rests in lower lifetime costs by 14.3-15.9%"
|
| |
| |
"Initiating treatment with LDV / SOF at fibrotic stages F0-F1 or F2 versus F3-F4 results in a
significant reduction in liver disease progression and related sequelae.......When initiating LDV / SOF treatment in F0-F1 or F2 as opposed to F3-F4, the model projected
lower incidence of liver disease progression, including new cases of decompensated cirrhosis
(DCC), hepatocellular carcinoma (HCC), liver transplants (LT), and HCV-related deaths (Table 5).
The estimated absolute reduction of these sequelae is 82.2% and 66.1% when initiating treatment
with LDV / SOF in F0-F1 or F2 as opposed to F3-F4, respectively (Figure 2).........When initiating treatment in F0-F1, F2, or F3-F4 in treatment-naïve patients, LDV/SOF is associated
with a lower lifetime cost relative to no treatment in all scenarios. The lifetime cost is lower the
earlier treatment is initiated (Table 6).......treating patients with LDV/SOF in early disease
reduces life-time costs, where lifetime costs are 14.3% and 15.9% lower when treatment is initiated
in F2 or F0-F1, respectively, as compared to treatment initiation with LDV / SOF in F3-F4."
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Ahmed Aijaz1, Stuart Gordon2, Sammy Saab3, Zobair Younossi4,5
1Stanford University, Stanford, CA; 2Henry Ford Hospital, Detroit MI; 3University of California, Los Angeles, Los Angeles, CA; 4Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA; 5Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA
|
| |
|
|
|
|
|
